Zimmer Biomet: Competing against Stryker’s MakoZimmer Biomet (NYSE:ZBH) is also seeking to compete against Stryker in the robot-assisted knee surgery space through its Rosa platform. The Rosa system boasts 2D X-ray and 3D pre-operative planning tools, allowing surgeons to conduct virtual procedures ahead of the actual surgeries — as well as real-time intraoperative data on soft tissue and bone anatomy.
Zimmer Biomet acquired the initial Rosa technology through its roughly $132 million purchase of French robot-assisted surgery firm Medtech in 2016.
As of August, the company had 150 Rosa knee systems placed around the world.
“Based on the volume of accounts in that pipeline, we’ll be very disappointed if we don’t have between 200 and 300 Rosa systems out in the market by the end of this year,” Zimmer Biomet CEO Bryan Hanson said during an August earnings call.
Zimmer Biomet also has a Rosa spine system and its Rosa One Brain system for neurosurgical procedures.